Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin

This study is examining whether a gene therapy called beremagene geperpavec (BVEC, which restores the COL7A1 gene) reduces the return or recurrence of squamous cell carcinoma (SCC) — a dangerous skin cancer — in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin-blistering disease. **You may be eligible if...** - You have a confirmed diagnosis of generalized recessive dystrophic epidermolysis bullosa (RDEB) with COL7A1 gene mutations - You have a biopsy-confirmed squamous cell carcinoma - You are 18 or older and based in the US - You are willing to use beremagene geperpavec (BVEC) treatment - You are able to use an effective method of contraception **You may NOT be eligible if...** - You are unable to travel to the study site for visits - You are pregnant - Your SCC has spread to other parts of the body (metastatic), or you are currently on systemic treatment for SCC Talk to your doctor to see if this trial is right for you.